ClinConnect ClinConnect Logo
Search / Trial NCT06721026

Re-evaluation of the Muscle-full Effect During Continuously Elevated Amino Acid Availability in Healthy Young Males

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Dec 3, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Amino Acid Infusion Tracer Methodology Muscle Biopsy

ClinConnect Summary

This clinical trial is studying how our bodies build muscle from protein, specifically looking at what happens when we eat multiple meals rich in amino acids (the building blocks of protein). Researchers want to understand the "muscle-full" effect, which is a situation where, after eating protein, our bodies may not continue to build muscle as expected after a short period. This study aims to replicate a previous finding that suggested muscle protein synthesis only increases for about two hours after a meal, even if we keep consuming protein.

The trial is looking for healthy young males aged 18 to 35 who have a body mass index (BMI) between 18.5 and 30. Participants will need to be in good health, meaning they won’t have any serious medical issues or use certain medications that could affect muscle protein metabolism. Those who join the study can expect to take part in meals with controlled protein intake while researchers monitor how their bodies respond. This information will help improve nutritional advice for both healthy individuals and those with specific health conditions in the future.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Male sex
  • Aged between 18 - 35 years
  • Healthy (assessed based on routine medical questionnaire)
  • BMI between 18.5 - 30 kg/m2
  • Exclusion Criteria:
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Smoking
  • Involved in progressive exercise training
  • A history of neuromuscular problems
  • Use of anticoagulants
  • Recent (\<12 months) participation in amino acid tracer (L-\[ring-13C6\] phenylalanineand L-\[3,5-2H2\]-tyrosine) studies
  • Use of medication known to affect (muscle) protein metabolism (e.g. corticosteroids, non-steroidal anti-inflammatory drugs, acne medication)
  • Phenylketonuria
  • Diagnosed with or history of liver damage
  • Diagnosed with or history of severe kidney damage and/or malfunction
  • Diagnosed with inability to break down amino acids

About Maastricht University Medical Center

Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.

Locations

Maastricht, Limburg, Netherlands

Patients applied

0 patients applied

Trial Officials

Luc van Loon, PhD

Principal Investigator

Maastricht University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported